Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
Charting the Future Multiple Sclerosis Market Landscape
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
REPORT FEATURES:
Interactive Product and Market Forecast Data Model
FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
Forecasts and Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Understand the Unique Benefits of Consensus Outlook
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
- An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
- A detailed forecast data analysis spreadsheet model comparing critical market parameters including
- Timely event-driven market forecast report and data analysis updates over the next 12 months
Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
REPORT FEATURES:
- Historical MS sales from 2006–2011
- Forecast MS sales from 2012-2016
- Key competitors and drug developers
- Predicted product positioning
- Current and late-stage pipeline drugs
- Future event mapping to forecast data points
- Comparative clinical trial results
Interactive Product and Market Forecast Data Model
FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
- Market size
- Product sales
- Company forecasts
- Company, brand, and drug class
- Mechanism of action
- Future events
Forecasts and Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Understand the Unique Benefits of Consensus Outlook
- Evaluate future sales forecasts and predicted market growth
- Map your market parameters and chart commercial prospects
- Assess market share by company and product
- Tailor your strategic and investment focus based on the competition
- Set proactive launch and branding strategies
- Keep up with event-driven market data updates
FORECAST DATA MODEL (EXCEL)
Tabs:
Contents:
Tabs:
- Market size
- Product sales
- Company forecast
- Mechanism of action
- Events
Contents:
- Analysis Highlights
- Multiple Sclerosis Marketplace
- Key Multiple Sclerosis Developers
- Multiple Sclerosis Class Dynamics
- Gilenya (fingolimod; Novartis Mitsubishi Tanabe) Forecast
- Tysabri (natalizumab; Biogen/Elan) Forecast
- Copaxone (glatiramer acetate; Teva) Forecast
- Avonex (interferon beta-1a; Biogen) Forecast
- Betaseron (interferon beta-1b; Bayer) Forecast
- Rebif (interferon beta-1a; Merck) Forecast
- Extavia (interferon beta-1b; Novartis) Forecast
- BG-12 (dimethyl fumarate; Biogen) Forecast
- Aubagio (teriflunomide; Sanofi) Forecast
- Laquinimod (Teva/Active Biotech) Forecast
- Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast
- Daclizumab HYP (Biogen/Abbott) Forecast
- Ocrelizumab (Biogen/Roche/Biogen) Forecast
